Showing 1–18 of 18 · Diagnostics & IVD
FY2025 revenue $44.33bn (+5.7%); operating margin 18.2%; net income $6.52bn.
Balance sheet figures not captured from release.
FY2026 revenue $19.46bn (+4.9%); operating margin 11.6%; net income $1.15bn.
Continuing operations; net income from continuing operations $1.42bn (+29%).
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
FY2025 revenue $2.58bn (+0.7%); operating margin 1.8%; net income $759.9m.
Net income lifted by non-operating investment gains; operating profit was $47m.
FY2025 revenue €4.07bn (+2.3%); contributive operating margin (CEBIT) 17.9%; net income €398.0m.
Balance sheet figures not captured from release.
FY2025 revenue €7.52bn (+7.0%); net margin 5.3%; net income €402.0m.
Net profit more than doubled; EBIT and leverage not captured.
Listed (HOLX); FY2025 full-year figures not yet captured, so not assessed.
Agreed in Oct 2025 to be acquired by Blackstone and TPG funds (up to $79 a share).
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
FY2025 revenue RMB 33.28bn (-9.4%); net margin 25.4%; net income RMB 8.45bn.
Net profit fell 30.3%; operating profit not stated in summary.
FY2025 revenue $2.09bn (+6.0%); adjusted operating margin 29.5%.
Net sales rounded in release; diluted EPS $1.94. Full GAAP figures in annual report.
FY2025 revenue $2.73bn (-1.9%); operating margin -33.7%; net loss $1.13bn.
Cash $169.8m; debt $2.65bn.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Parent Roche (ROG.SW) group FY2025 revenue CHF 61.52bn (+2.0%); core operating margin 35.5%; net income CHF 13.80bn.
Diagnostics division sales CHF 13.85bn (+2% at constant exchange rates).
FY2025 revenue ¥560.7bn; operating margin 13.1%; net income ¥60.5bn.
Balance sheet figures not captured from release.
FY2026 revenue €23.60bn; adjusted EBIT margin 16.2%.
Comparable revenue growth 4.0%; adjusted EBIT about €3.8bn. Net income not captured.
FY2025 revenue ¥500.0bn (-1.7%); operating margin 10.4%; net income ¥35.5bn.
Balance sheet figures not captured from release.
FY2025 revenue $44.56bn (+3.9%); operating margin 17.4%; net income $6.70bn.
Cash $9.85bn; debt $39.38bn.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.